Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Disitamab Vedotin”

81 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 81 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06492317
What this trial is testing

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 20
Testing effectiveness (Phase 2)UnknownNCT05726175
What this trial is testing

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Who this might be right for
Breast Cancer
West China Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT07117851
What this trial is testing

Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease

Who this might be right for
Extramammary Paget DiseaseScrotum Disease
Fudan University 20
Post-approval studies (Phase 4)Not Yet RecruitingNCT05488353
What this trial is testing

A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Looking for participantsNCT06734182
What this trial is testing

Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital 25
Testing effectiveness (Phase 2)Looking for participantsNCT06354231
What this trial is testing

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Who this might be right for
Renal InsufficiencyUpper Urinary Tract Urothelial CarcinomaSolitary Kidney
Fudan University 20
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Not applicableLooking for participantsNCT06558682
What this trial is testing

Neoadjuvant Therapy in Cervical Cancer

Who this might be right for
Uterine Cervical Neoplasms
Qilu Hospital of Shandong University 48
Testing effectiveness (Phase 2)Looking for participantsNCT06992362
What this trial is testing

Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach

Who this might be right for
Hepatoid Adenocarcinoma of Stomach
Peking University Cancer Hospital & Institute 30
Testing effectiveness (Phase 2)UnknownNCT05627414
What this trial is testing

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Who this might be right for
Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 172
Testing effectiveness (Phase 2)Looking for participantsNCT06389006
What this trial is testing

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 79
Not applicableNot Yet RecruitingNCT06015113
What this trial is testing

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

Who this might be right for
Breast Cancer
Xi'an International Medical Center Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05912205
What this trial is testing

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Who this might be right for
Urothelial Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Testing effectiveness (Phase 2)Looking for participantsNCT06560528
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT05912816
What this trial is testing

Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Who this might be right for
Upper Urinary Tract Urothelial CarcinomaKidney PreservationHER-2 ADC+1 more
RenJi Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06383533
What this trial is testing

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Who this might be right for
Bile Duct Adenocarcinoma Non-ResectableHER2 Gene Mutation
Zhejiang Cancer Hospital 28
Post-approval studies (Phase 4)UnknownNCT05723991
What this trial is testing

Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma

Who this might be right for
Radical CystectomyUrothelial Carcinoma
Chunguang yang (101937) 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07100184
What this trial is testing

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Who this might be right for
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
Peking University First Hospital 30
Load More Results